The rise of Sildenafil initially sparked a boom for major pharmaceutical companies, but recent shifts present a uncertain outlook for investors. Lower-cost competitors are reducing earnings, and continued litigation https://robertsfln405555.theisblog.com/41606491/the-blue-pill-and-big-pharma-a-volatile-play